These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6769681)

  • 21. A comparison of the effects of four ergot derivatives on prolactin secretion by dispersed rat pituitary cells.
    Delitala G; Yeo T; Grossman A; Hathway NR; Besser GM
    J Endocrinol; 1980 Oct; 87(1):95-103. PubMed ID: 7430919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ergot alkaloids as dopamine agonists: comparison in two rodent models.
    Anlezark G; Pycock C; Meldrum B
    Eur J Pharmacol; 1976 Jun; 37(2):295-302. PubMed ID: 986304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presynaptic effects of tetrahydropapaveroline on striatal dopaminergic neurons.
    Hoffman IS; Cubeddu LX
    J Pharmacol Exp Ther; 1982 Jan; 220(1):16-22. PubMed ID: 7053412
    [No Abstract]   [Full Text] [Related]  

  • 24. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A; Fadda F; Melis MR; Marcou M; Porceddu ML; Gessa GL
    Eur J Pharmacol; 1982 Nov; 85(1):23-7. PubMed ID: 6818043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase in striatal dopamine D2 receptor mRNA after lesions of haloperidol treatment.
    Coirini H; Schumacher M; Angulo JA; McEwen BS
    Eur J Pharmacol; 1990 Sep; 186(2-3):369-71. PubMed ID: 2127022
    [No Abstract]   [Full Text] [Related]  

  • 26. Ergot alkaloids and cyclic nucleotides in the CNS.
    Trabucchi M; Hofmann M; Montefusco O; Spano PF
    Pharmacology; 1978; 16 Suppl 1():150-55. PubMed ID: 205889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. d-Amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities.
    Demarest KT; Lawson-Wendling KL; Moore KE
    Biochem Pharmacol; 1983 Feb; 32(4):691-7. PubMed ID: 6403019
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.
    Galloway MP; Wolf ME; Roth RH
    J Pharmacol Exp Ther; 1986 Mar; 236(3):689-98. PubMed ID: 3081705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
    Fuxe K; Fredholm BB; Agnati LF; Corrodi H
    Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effect of dopamine on acetylcholine release from caudate nucleus.
    Vizi SE; Rónai A; Hársing L; Knoll J
    Pol J Pharmacol Pharm; 1977; 29(3):201-11. PubMed ID: 887499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade.
    Reches A; Wagner HR; Jackson-Lewis V; Fahn S
    Brain Res; 1985 Nov; 347(2):346-9. PubMed ID: 3933764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Suppressive effects of lisuride on the synthesis, release and metabolism of dopamine in rat brain].
    Azuma H; Iwai K; Sato K; Kikuta M; Liu HJ; Oshino N
    Nihon Yakurigaku Zasshi; 1982 Nov; 80(5):325-39. PubMed ID: 6131854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of antiparkinsonian ergot derivatives to the dopamine receptor.
    Weir RL; Hruska RE; Silbergeld EK
    Psychopharmacology (Berl); 1981; 75(2):119-23. PubMed ID: 6798600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective influence of ergot alkaloids on cortical and striatal dopaminergic and sergotonergic receptors.
    Rosenfeld MR; Makman MH; Ahn HS; Thal LJ; Mishra RK; Katzman R
    Adv Biochem Psychopharmacol; 1980; 23():83-93. PubMed ID: 6249092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supersensitivity of dopamine-autoreceptors. The effect of gammabutyrolactone in long-term haloperidol treated rats.
    Stock G; Steinbrenner J; Kummer P
    J Neural Transm; 1980; 47(2):145-51. PubMed ID: 7373289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive changes of the striatal dopamine system induced by repeated administration of neuroleptics and ergot derivatives.
    Bürki HR
    Adv Biochem Psychopharmacol; 1980; 24():65-8. PubMed ID: 6105806
    [No Abstract]   [Full Text] [Related]  

  • 37. Sensitivity of regional brain dopamine systems to haloperidol.
    Kolenik SA; Hoffman FJ; Bowers MB
    Biol Psychiatry; 1989 Mar; 25(6):815-7. PubMed ID: 2923943
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibitory effects of brotizolam, a new thienodiazepine, on limbic forebrain and neostriatal dopaminergic systems in vivo and in vitro.
    Ishiko J; Inagaki C; Takaori S
    Neuropharmacology; 1983 Feb; 22(2):221-6. PubMed ID: 6835488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for dopamine autoreceptors in mesocortical dopamine neurons.
    Fadda F; Gessa GL; Marcou M; Mosca E; Rossetti Z
    Brain Res; 1984 Feb; 293(1):67-72. PubMed ID: 6423212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids.
    Holohean AM; White FJ; Appel JB
    Eur J Pharmacol; 1982 Jul; 81(4):595-602. PubMed ID: 7117388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.